- Home
- OPFI vs IKT Comparison
OPFI vs IKT Comparison
Compare OPFI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPFI | IKT |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | 445 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.2M | 240.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPFI | IKT |
|---|---|---|
| Price | $8.31 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $14.25 | $5.00 |
| AVG Volume (30 Days) | ★ 687.4K | 675.8K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $97.52 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $67.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.36 | $1.33 |
| 52 Week High | $14.63 | $2.26 |
Technical Indicators
Market Signals| Indicator | OPFI | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 38.77 |
| Support Level | $8.06 | $1.51 |
| Resistance Level | $8.52 | $1.74 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 42.47 | 36.54 |
Price Performance
Historical ComparisonAbout OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.